ATI is pleased to announce that our initial financing from Mitsubishi UFJ Capital (MUCAP) has been successfully closed. ATI will complete the master cell bank process to begin manufacturing of ATI-235, our lead asset in fibrosis, with IPF as the lead indication. Using the GLP manufactured antibody, ATI will complete the final preclinical process, safety/toxicity testing, also known as the “Death Valley” of drug development. We will make sincere efforts on every single step. We appreciate MUCAP for their action based on the insight and expectation.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
